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Stromal cells within the tumor microenvironment
are essential for tumor progression and metastasis.
Surprisingly little is known about the factors that
drive the transcriptional reprogramming of stromal
cells within tumors. We report that the transcriptional
regulator heat shock factor 1 (HSF1) is frequently
activated in cancer-associated fibroblasts (CAFs),
where it is a potent enabler of malignancy. HSF1
drives a transcriptional program in CAFs that com-
plements, yet is completely different from, the pro-
gram it drives in adjacent cancer cells. This CAF
program is uniquely structured to support malig-
nancy in a non-cell-autonomous way. Two central
stromal signaling molecules—TGF-b and SDF1—
play a critical role. In early-stage breast and lung
cancer, high stromal HSF1 activation is strongly
associated with poor patient outcome. Thus, tumors
co-opt the ancient survival functions of HSF1 to
orchestrate malignancy in both cell-autonomous
and non-cell-autonomous ways, with far-reaching
therapeutic implications.
INTRODUCTION
Cancer cells in a tumormass are surrounded by a variety of other
cell types, including immune cells, fibroblasts, and endothelial
cells as well as extracellular matrix (ECM) components. Taken
together, these comprise the tumor microenvironment. Cells of
the tumor microenvironment contribute to the hallmarks of can-
cer, and their coevolution with cancer cells is essential for tumor564 Cell 158, 564–578, July 31, 2014 ª2014 Elsevier Inc.formation and progression (Bissell and Hines, 2011; Hanahan
and Weinberg, 2011).
In the majority of carcinomas, the most abundant cells in the
tumor microenvironment are cancer-associated fibroblasts
(CAFs) (Hanahan and Coussens, 2012; Hanahan and Weinberg,
2011). CAFs include myofibroblasts and reprogrammed variants
of normal tissue-derived fibroblasts that are recruited by the tu-
mor to support cancer cell proliferation, angiogenesis, invasion,
metastasis, and drug resistance (Erez et al., 2010; Kalluri and
Zeisberg, 2006; Olumi et al., 1999; Straussman et al., 2012;
Wilson et al., 2012). CAFs support cancer cells in a non-cell-
autonomous manner through secretion of ECM, chemokines,
cytokines, and growth factors (Lu et al., 2012; Moskovits et al.,
2006; Orimo et al., 2005; Pickup et al., 2013; Siegel and Mas-
sague´, 2003). The secretion of cytokines also feeds back to
promote the fibroblast-to-CAF transition, through autocrine
transforming growth factor b (TGF-b) and stromal-derived factor
1 (SDF1) signaling (Kojima et al., 2010).
Despite accumulating evidence for the non-cell-autonomous
effects of CAFs on cancer cells, little is known about the tran-
scriptional regulators that are responsible for stromal reprog-
ramming to support tumorigenesis. That such reprogramming
must occur is clear from evidence that normal fibroblasts usually
constitute a tumor-restrictive environment (Bissell and Hines,
2011). In mouse models, tumor suppressors such as p53 and
PTEN can act in the stroma to limit tumor growth (Lujambio
et al., 2013; Moskovits et al., 2006; Trimboli et al., 2009). If tumor
suppressors act in both the cancer cells and the stroma to inhibit
malignancy, might there also be factors that actively support
or enable malignancy in both cancer cells and in the stroma?
Presumably, these would not be classical oncogenes because
nonmalignant stromal cells are relatively stable genetically (Qiu
et al., 2008). Instead, we wondered if tumors might hijack normal
physiological pathways and programs in the stroma, subverting
them to enable neoplastic growth and metastatic dissemination.
Here, we provide evidence for such a mechanism by investi-
gating the stromal function(s) of heat shock factor 1 (HSF1) in
tumor biology.
HSF1 is a ubiquitously expressed transcription factor best
known for its activation by heat (Sakurai and Enoki, 2010; Sha-
movsky and Nudler, 2008). Recently, it has been shown to play
a fundamental role in tumor biology (Dai et al., 2007; Jin et al.,
2011). In a wide variety of human cancer cell lines, the depletion
of HSF1 markedly reduces growth, survival, and metastatic po-
tential (Mendillo et al., 2012; Meng et al., 2010; Santagata et al.,
2012; Scott et al., 2011). Hsf1 null mice develop normally but are
profoundly resistant to tumorigenesis.
The transcriptional program that is activated by HSF1 in can-
cer cells is surprisingly different from the program activated by
classical heat shock (Mendillo et al., 2012). In particular, it acts
to support the malignant state by blunting apoptotic responses
and promoting pathways that facilitate anabolic metabolism,
protein folding, proliferation, invasion, and metastasis (Dai
et al., 2012; Fang et al., 2012; Jin et al., 2011; Mendillo et al.,
2012; Meng et al., 2010; Santagata et al., 2013; Scott et al.,
2011). In humans, activation of this program by HSF1 in cancer
cells is strongly associated with disease progression in patients
with breast, colon, lung, and hepatocellular carcinomas (Fang
et al., 2012; Mendillo et al., 2012; Santagata et al., 2011).
Clearly, HSF1 plays a central role in supporting the malignant
transformation and progression of diverse cancer types. Here,
we ask if it plays a complementary, and perhaps equally impor-
tant, role in subverting the normally repressive activity of the
stroma by converting it to a protumorigenic state. We also
discuss the possible evolutionary origins of HSF1-mediated
crosstalk between cancer and stromal cells in tumors, as well
as its potential therapeutic implications.
RESULTS
HSF1 Is Activated in CAFs within Human Tumors
Under basal conditions in normal cells, HSF1 resides primarily in
the cytoplasm. Upon activation, it accumulates in the nucleus
(Morimoto, 2008; Santagata et al., 2011). To determine whether
HSF1 is activated in cells of the tumor microenvironment, we
scored the staining intensity of this transcription factor in the
nuclei of tumor-associated stroma within patient-derived breast
cancer samples. Stromal cells residing in the lobules of neigh-
boring, normal breast tissue were used for comparison. These
normal cells were almost invariably low or negative for nuclear
HSF1. However, strong nuclear HSF1 staining was frequently
present in stromal cells situated in close proximity to malignant
cells (Figures 1A, upper panel, and 1B).
The morphology of the HSF1-positive stromal cells suggested
that they were CAFs. To confirm, we costained tumor sections
for HSF1 and smooth muscle actin (SMA). SMA stains normal
myoepithelial cells (Figure 1A, lower-right panel). It is not present
in normal fibroblasts, however, and is often used as a marker for
stromal CAFs (Kalluri and Zeisberg, 2006; Quante et al., 2011).
We also investigated markers of two other stromal components:
leukocytes (LCA) and endothelial cells (CD31). Most of the HSF1-
positive stromal cells in the tumors costained with SMA, sug-gesting that they are indeed CAFs (Figure 1A, lower-left panel;
Figure S1 available online).
To test the generality of HSF1 activation in CAFs across
different tumor types, we costained tumor sections from lung,
skin, esophageal, colon, gastric, and prostate carcinomas with
antibodies for HSF1 and SMA (Figure 1C). In all of these, most
SMA-positive CAFs also had strong nuclear HSF1 staining.
Loss of Hsf1 in Fibroblasts Reduces Xenograft Tumor
Growth
To explore the function of stromal HSF1 activation in a tractable
model system, we analyzed xenografts of human MCF7 breast
cancer cells injected subcutaneously into immunocompromised
(nonobese diabetic [NOD]-severe combined immunodeficiency
[SCID]) mice. As expected, xenografts recruited endogenous
stromal cells from their mouse hosts to support tumor formation.
These SMA-positive CAFs exhibited strong nuclear HSF1 stain-
ing (Figure S2A).
To test whether HSF1 activation in stromal cells plays a role in
supporting malignant cells, we mixed primary mouse embryonic
fibroblasts (MEFs)—either wild-type (WT) or Hsf1 null—with the
MCF7 cancer cells and coinjected them subcutaneously into
NOD-SCIDmice (Figure 2A). Tumors arising fromMCF7 cells co-
injected with Hsf1 null MEFs (Figure 2A, blue) grew significantly
more slowly than those of mice coinjected with WT MEFs (Fig-
ure 2A, red).
MCF7 cells injected without MEFs formed tumors more slowly
thanMCF7 cells coinjected withWTMEFs (Figure 2A). With time,
cells injected without MEFs recruited WT host stroma, and the
tumors grew to the same size as those formed by coinjection
with WT MEFs. However, throughout the experiment, tumors
formed by MCF7 cells coinjected with Hsf1 null MEFs remained
significantly smaller.
To better understand this result, we excised tumors at the end
of the experiment and examined their histology (Figure 2B, upper
panels). Tumors frommice injected with MCF7 cells only and tu-
mors frommice coinjected with WTMEFs shared a poorly differ-
entiated and sheet-like morphology typical of high-grade tu-
mors. In contrast, coinjection of MCF7 cells and Hsf1 null
MEFs produced tumors with a more differentiated, stromal-rich
architecture, indicative of a less malignant phenotype. Notably,
some of the stromal fibroblasts were HSF1 positive, indicating
that in addition to the injected MEFs, the tumors had recruited
host fibroblasts (Figure S2B). (This might explain why, even
though slower, these tumors still grew.) Masson’s trichrome
staining indicated that stroma-rich regions aremostly comprised
of fibrous tissue and deposits of collagen (Figure 2B, lower
panels). These results suggest that, in response to cancer cells,
HSF1 is activated in stromal CAFs to support tumor growth.
Moreover, in the absence of this HSF1-driven response, fibro-
blasts actually exert an inhibitory effect on tumor expansion.
Stromal HSF1 Regulates Cancer Cell Growth In Vitro
To learn how activation of HSF1 in stromal fibroblasts supports
cancer cells, we plated fluorescently labeled breast cancer cells
onto feeder layers of either WT orHsf1 null MEFs (Figures 3A and
S3A). We found a higher number of cancer cells in cocultures
withWTMEFs thanwithHsf1 null MEFs. This held true for severalCell 158, 564–578, July 31, 2014 ª2014 Elsevier Inc. 565
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different mammary cancer cell lines (mouse D2A1, Figures 3A
and 3B; human MCF7, human HCC38, and mouse 4T7; Figures
S3B and S3C).
To confirm true HSF1 dependence, we used MEFs that were
deleted for WT Hsf1 but expressed a tetracycline-repressible
Hsf1 transgene (Bi-TetO-Hsf1). We repressed Hsf1 expression
for 5 days and then cocultured the MEFs with D2A1 cancer cells.
Repression of Hsf1 resulted in decreased accumulation of can-
cer cells (Figure S3D). Thus, even short-term loss ofHsf1 impairs
the ability of fibroblasts to support the growth of cocultured can-
cer cells.
Stromal HSF1 Drives a Transcriptional Program in
Cancer Cells that Promotes Malignant Phenotypes
To test the effects of coculture on gene expression, we sepa-
rated cancer cells from fibroblasts by fluorescence-activated
cell sorting (FACS), extracted RNA, and hybridized it to gene
expression arrays. As a point of comparison, each cell type
was grown alone (without coculture), treated, and analyzed in a
similar manner.
In D2A1 cancer cells, regardless of theHsf1 status of the cocul-
turedMEFs, the expressionof700geneswasalteredbyR2-fold
following coculture (Figure 3C, group b; Table S1). Of these,400
genes were upregulated, and 300 genes were downregulated.
The upregulated set was enriched for genes involved in cellular
differentiation, migration, and ECM organization. No significant
functional enrichment was found in the downregulated set.
With specific regard to the Hsf1 status of the MEFs, approxi-
mately 200 genes were upregulated in cancer cells cocultured
with WT, but not with Hsf1 null MEFs (Figure 3C, group a). This
set was enriched for genes involved in ECM organization, devel-
opment, and adhesion (e.g., Dmp1, Dkk3, Thy1, Grem1, Sparc,
Mmp2, and Mmp3; Figure 3D; Table S1). In cancer cells cocul-
tured with Hsf1 null MEFs, 750 genes were uniquely upregu-
lated (Figure 3C, group c). Proinflammatory cytokines (e.g.,
Ccl5 and Ccl8) and immune responses (e.g., the response to
type 1 interferon) were most significantly enriched in this group
(Figure 3D; Table S1). Thus, activation of HSF1 in the stroma
helps to reprogram cancer cells in at least two important ways.
In a non-cell-autonomous manner, it upregulates genes in can-
cer cells that enhance their malignant potential and downregu-
lates genes that would trigger host immune defense responses.
Stromal HSF1 Drives a Transcriptional Program in
Fibroblasts that Supports Malignant Cells
Next, we examined a complementary question: how does cocul-
ture with cancer cells affect HSF1-dependent gene expression inFigure 1. HSF1 Activation in CAFs within Human Tumors
(A) Tissue sections of breast resection specimens from 12 patients encompassing
same section) were immunostained with anti-HSF1 antibodies (brown, upper pan
Representative images are shown. Arrows indicate HSF1-positive CAFs in the le
indicate cancer- and stroma-rich regions, respectively. For normal tissue, E and
(B) Pie charts depict the distribution of relative nuclear HSF1 staining intensity in
each specimen, four regions of tumor or normal tissue were evaluated. Statistical
repeated measures ANOVA (p = 4 3 1013), as well as paired t tests, followed b
(C) Representative images of tumor sections from patients with the indicated typ
See also Figure S1.stromal fibroblasts? Profiling of FACS-sorted MEFs showed that
even in the absence of cancer cells, HSF1 regulated many genes
involved in development, cell adhesion, and proliferation (e.g.,
Fgf, Igf, Col, Lama, Snail, and Sdf1; Figure 3E, group 1; Tables
S2 and S3). This suggests that HSF1 alters the basal phenotype
of MEFs in culture, and these alterations enhance the growth of
cancer cells. In an HSF1-dependent manner, coculture with
cancer cells induced an additional cluster of genes involved in
development, proliferation, and response to wounding (e.g.,
Tgf-b1, Cxcl1, Cxcl3, and Vcam1; Figure 3E, group 4; Tables
S2 and S3). Also in an HSF1-dependent manner, cancer cells
induced in MEFs a striking downregulation of genes involved in
cellular immune responses (e.g.,Cxcl10,Bst2, andC3; Figure 3E,
group 3; Tables S2 and S3). Thus, WT MEFs respond to cancer
cells in a manner that supports tumor growth, whereas Hsf1 null
MEFs respond in a manner likely to impede the process.
To further characterize the HSF1 stromal signature, we per-
formed additional analyses of the genes that are differentially
upregulated in WT versus Hsf1 null MEFs cocultured with can-
cer cells (Figure 3E, groups 1 and 4). We compared this list to
publicly available gene sets of stroma from human cancer pa-
tients, fibroblast wound-healing responses, and the heat shock
response. Although some heat shock-related genes were en-
riched, this was not the most prominent response. Rather, the
HSF1 stromal signature was most highly enriched for genes
previously characterized by their upregulation in fibroblasts in
response to wounding and in stromal cells isolated from human
tumors (Beck et al., 2008; Chang et al., 2004; Dvorak, 1986; Kar-
noub et al., 2007) (Figure 3F; Table S4). We also compared this
list to the HSF1-dependent gene expression signature in cancer
cells (Mendillo et al., 2012) and found that these signatures were,
if anything, anticorrelated (Table S4). Thus, in fibroblasts, HSF1
activates a transcriptional program likely to support tumor pro-
gression, which is profoundly different from the response acti-
vated by HSF1 in the cancer cells themselves or in cells exposed
to heat.
The Effects of Stromal HSF1 Activation on Cancer Cells
Are Mediated by TGF-b and SDF1 Signaling
Unbiased analysis of gene set enrichment established that TGF-
b signaling was one of the top categories regulated by HSF1 in
MEFs cocultured with cancer cells (group 4 in Figure 3E; Table
S5). Because TGF-b, along with SDF1, was previously found to
promote CAF phenotypes (Kojima et al., 2010), we further inter-
rogated both signaling pathways. We extracted RNA from both
immortalized and three separate sets of primary WT or Hsf1
null MEFs and performed quantitative PCR (qPCR) with primersboth invasive ductal carcinoma and neighboring normal breast lobules (in the
els) or costained with anti-HSF1 and anti-SMA (pink) antibodies (lower panels).
ft panels and HSF1-negative normal fibroblasts in the lower panels. C and S
F indicate regions rich with epithelial cells or fibroblasts, respectively.
the stroma among 12 breast resection specimens with matching controls. For
significance of the differences between normal and tumor was assessed using
y Bonferroni correction (p < 0.01).
es of cancer costained for HSF1 (brown) and SMA (pink).
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targeting Tgf-b1, Tgf-b2, Tgf-b3, and Sdf1. This confirmed that
expression levels of Sdf1, Tgf-b1, and Tgf-b2 were significantly
lower inHsf1 null MEFs than inWTMEFs, even without coculture
with cancer cells (Figures 4A and S4A).
Next, we asked if TGF-b and SDF1 mediate HSF1’s stromal
support of cancer cells. We added these factors as purified
recombinant proteins to cocultures of D2A1 cancer cells with
Hsf1 null MEFs. Combined addition of TGF-b1 and SDF1
restored cancer cell growth to levels achieved by coculture
with WT MEFs (Figures 4B and 4C). Partial effects, which did
not reach statistical significance, were achieved by addition of
either factor alone (Figure S4B).
As a further functional test, we repressed TGF-b signaling in
cocultures by adding a TGF-b receptor type I (TbRI)/TbRII dual
inhibitor, LY2109761, to the media (Dituri et al., 2013). To control
for direct effects on cancer cells themselves, we treated cancer
cells with the inhibitor in the absence of MEFs. Treatment with
LY2109761 did not affect cancer cells grown alone (Figure S4C).
It did, however, significantly reduce their growth in coculture with
WT MEFs (Figure 4D; p = 0.008). A smaller effect, which did not
reach statistical significance, was seen in coculture with Hsf1
null MEFs (Figure 4D; p = 0.1). Taken together with the increased
expression of Tgf-b and Sdf1 in WTMEFs compared to Hsf1 null
MEFs (Figure 4A), these results suggest that TGF-b and SDF1
are produced and secreted by fibroblasts in an HSF1-dependent
manner.
Once secreted, TGF-b and SDF1 could activate the fibroblasts
themselves, the cancer cells, or both. To investigate, we
knocked down the expression of several signaling molecules
downstream of TGF-b and SDF1 in either cancer cells or MEFs
(see Experimental Procedures). Knockdown of Smad2, a key
downstream mediator of TGF-b signaling, in WT MEFs impaired
the growth of cocultured D2A1 cancer cells (Figures 4E andS4E).
This growth defect could not be rescued by addition of recombi-
nant TGF-b1 and SDF1 (Figure 4E). Notably, Smad2 knockdown
was only effective in the MEFs. Knockdown of the same gene in
the D2A1 cells themselves had no effect on cell number (Figures
S4D and S4E). We conclude that HSF1 supports an autocrine
TGF-b signaling loop in MEFs. As for SDF1, although we cannot
discriminate whether it signals to the cancer cells or to the
stroma, SDF1 expression is clearly upregulated by HSF1 in fibro-
blasts. Taken together, our data indicate that TGF-b and SDF1
are key mediators of the tumor-promoting activity of stromal
HSF1.
HSF1 Directly Binds HSEs of the Sdf1 Gene in
Stromal Cells
Next, we asked whether TGF-b and SDF1 are direct transcrip-
tional targets of HSF1. A bioinformatic search for HSF1-bindingFigure 2. Stromal Hsf1 Status Alters Tumor Progression and Histology
MCF7 breast cancer cells alone or mixed with WT or Hsf1 null primary MEFs were
twice, with four mice per group in each experiment.
(A) Themean tumor volume (total eight per treatment group) is shown. The distribu
days 22 and 38 postinjection. Error bars, SEM. *p < 0.05; **p < 0.01.
(B)Micewere sacrificedwhen tumor burden reached size limit, and the tumorswer
Masson’s trichrome stain (lower panels). All images were collected at the same
See also Figure S2.elements (HSEs) in genes of the TGF-b and SDF1 signaling path-
ways confirmed that the Tgf-b2 and Sdf1 genes themselves
contain canonical HSEs. No HSEs were found in Tgf-b1 or any
of the downstream signaling molecules mentioned above. To
determine whether HSF1 directly regulates Tgf-b2 and Sdf1
expression in CAFs, we performed chromatin immunoprecipita-
tion (ChIP) using anti-HSF1 antibodies and extracts prepared
from MCF7 tumor xenografts. To focus specifically on the sup-
porting mouse stromal cells, and not the human cancer cells,
we performed qPCR using primers flanking potential HSF1-bind-
ing sites that were specific to the mouse genes (Figure S4F).
Primers for an intergenic region served as a negative control.
Sdf1 was significantly amplified from stromal (mouse) DNA
bound by HSF1 (Figure 4F). No significant amplification was
detected for Tgf-b2. Together with the effects of HSF1 seen on
expression of these genes, these data suggest that regulation
of Tgf-b by HSF1 may be indirect. However, HSF1 directly binds
and activates Sdf1.
HSF1 Activation in Breast Cancer Stroma Is Associated
with Poor Patient Outcome
Our findings in mouse xenografts and in vitro coculture models
indicate that stromal HSF1 contributes to tumor progression.
To evaluate whether stromal HSF1 contributes to disease pro-
gression in human cancers, we first asked whether HSF1
mRNA levels in the stroma correlate with disease outcome. We
looked for this association in a publicly available mRNA data
set from 53 pure tumor stroma samples obtained from patients
with primary breast tumors (stromal cells were separated from
cancer cells by laser microdissection; Finak et al., 2008).
In this data set, high HSF1 levels significantly correlated with
increased tumor grade (Figure 5A) and poorer patient outcome
(Figure 5B). We further asked whether high stromal Hsf1 expres-
sion is associated with a specific breast cancer subtype. No
significant association was found with estrogen receptor (ER;
Figure S5A) or progesterone receptor (PR; Figure S5B) expres-
sion. (The number of triple-negative tumors in this cohort
was too small to determine a possible association with HSF1
expression.) HSF1 expression was, however, significantly higher
in HER2-positive tumors as compared to HER2-negative tumors
(Figure 5C).
HSF1 is often activated posttranscriptionally without a change
in its mRNA level. To provide an independent assessment of the
importance of its activation in breast cancer stroma, we assem-
bled a breast cancer cohort to evaluate HSF1 activation at the
protein level by immunohistochemistry (IHC). We examined a
total of 46 samples from patients with early-stage breast cancer
(Table S6), for whom we had both appropriate tissue sections as
well as a minimum of 8 years of continuous clinical follow-up.in Human Breast Xenografts
injected subcutaneously into NOD-SCID mice. The experiment was repeated
tion of individual measurements is shown in the lower panels, in scatterplots for
e excised, fixed, and stainedwith hematoxylin and eosin (H&E; upper panels) or
magnification. Scale bar, 50 mm.
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Tumor sections were scored in a blinded manner for nuclear
HSF1 staining intensity in the cancer cells and in the stromal
cells.
We found markedly reduced disease-free survival, as well as
overall survival, in patients whose tumors had high stromal
HSF1 activation (Figures 5D and S5C). In this cohort, HSF1 acti-
vation in stromal cells was correlated with HSF1 activation in the
cancer cells (p = 0.01, chi-square test). Indeed, high HSF1 acti-
vation in the cancer cells also correlated with lower overall sur-
vival, consistent with our previous findings (Mendillo et al.,
2012; Santagata et al., 2011). However, the association with pa-
tient outcome was weaker in cancer cells than in the stroma
(Figures S5D and S5E). Moreover, in a multivariate model
considering the independent contributions of HSF1 activation
in the cancer cells and in the stroma to overall survival, only stro-
mal HSF1 (and not cancer cell HSF1) was a significant predictor
of survival (Table S6). Stromal HSF1 was also an independent,
significant predictive factor in a multivariate model considering
various clinicopathologic factors (Table S6). The significant as-
sociation of stromal HSF1 activation with poor patient outcome
seen in two independent cohorts using very different methodol-
ogies suggests that stromal HSF1 could be a useful, indepen-
dent prognostic indicator in breast cancer.
HSF1 Activation in Early-Stage Lung Cancer Stroma Is
Associated with Poor Outcome
Might stromal HSF1 serve as a potential prognostic marker in
other tumor types? Our initial survey of human cancers showed
that HSF1 is activated in the CAFs of many tumor types, in-
cluding lung, colon, skin, esophageal, gastric, and prostate (Fig-
ures 1C and 6A). Of these tumor types, we had access to a
cohort of lung cancer patients with appropriate tissue samples
for stromal assessment of HSF1, together with clinical follow-
up data. Encouraging the analysis of this data set, pilot testing
of human non-small cell lung cancer (NSCLC) lines (A549 and
H1703) showed that these lines grew more robustly when cocul-
tured with WT MEFs than when cocultured with Hsf1 null MEFs
(Figure S6A).
A total of 72 samples from patients with stage I non-small cell
lung adenocarcinoma (Table S7) (Sholl et al., 2010) were scored
in a blinded manner for HSF1 activation (nuclear staining inten-Figure 3. HSF1 in Fibroblasts Supports Cancer Cell Growth by Activatin
(A and B)WT orHsf1 null immortalizedMEFswere treatedwith 10 mg/ml mitomycin
were seeded on top of theMEFs and allowed to grow for 72–96 hr, after which can
quantitated by flow cytometry (B). The mean of three independent experiments i
(C and D) Total RNA was purified from duplicate cultures of D2A1 cancer cells gro
was hybridized to Agilent microarrays, and relative gene expression levels were a
was set to 1, and the relative change in expression upon coculture with WT or H
(C) Overlap of genes differentially expressed in D2A1 cancer cells in the presenc
(D) Heatmap depicting fold change inmRNA levels of genes differentially expresse
Gene Ontology (GO) enrichment is shown to the right of the panel. Groups a and
(E) WT or Hsf1 null MEFs were cocultured with D2A1-dsRed cells as described in
mRNA was extracted and hybridized to Agilent microarrays. MEFs cultured with
expression was analyzed using Cluster 3.0, and the differentially expressed gene
panel.
(F) Gene set enrichment analysis of genes upregulated inWT versusHsf1 null MEF
for the indicated gene sets and is presented as normalized enrichment score (NES
is shown in red; nonsignificant enrichment is shown in gray.
See also Figure S3 and Tables S1, S2, S3, S4, and S5.sity) in cancer cells and stromal cells. Patients with stage I
NSCLC have a 5-year survival of 60%–70% (Goldstraw et al.,
2007). Stromal HSF1 activation did not correlate with demo-
graphic factors such as age, sex, or smoking status (Table S7).
It did, however, show a significant correlation with patient
outcome.
Disease-free survival was significantly shorter in lung cancer
patients whose tumors had either high or intermediate HSF1
activity in the stroma (Figure 6B). A similar trend was found for
survival of patients with high HSF1 in the cancer cells (Fig-
ure S6B). In this cohort, HSF1 activation in the cancer cells did
not correlate with HSF1 activation in the stroma (p = 0.28, chi-
square test). We therefore asked if evaluation of HSF1 activation
in both cell types could improve our ability to predict patient
outcome. Although the number of patients is small, it is striking
that there was not a single recurrence in any of the patients
that had low HSF1 activity in both the cancer cells and in the
stroma over the course of follow-up (Figure 6C).
To assess the independent contributions to outcome of
increased HSF1 activation in cancer cells versus stromal cells,
we fitted a multivariate Cox proportional hazards regression
model to recurrence-free survival, considering stromal HSF1
activation separately from cancer cell activation. Cancer cell
HSF1 was not independent from stroma in its association with
disease progression. However, as in our breast cancer cohort,
stromal HSF1 activation was significantly and independently
associated with disease-free survival (Table S7).
To further refine our analysis, we genotyped the collection of
tumor samples for the most commonly mutated oncogenes in
lung adenocarcinoma, KRAS and EGFR (Pillai and Ramalingam,
2014), and tested the association of HSF1 activation and disease
outcome with different mutations. In the 52 samples from our
cohort that were successfully genotyped, KRAS mutations, but
not EGFR mutations, correlated with poor disease-free survival
(Figures S6C and S6D). We found no correlation between HSF1
activation (in either cancer cells or stroma) and KRAS or EGFR
mutations per se. We did, however, find a significant association
between high activity of HSF1 in the stroma and poor outcome in
patients with KRAS mutant tumors (Figure 6D). Moreover,
stromal HSF1 (but not cancer cell HSF1) was an independent
predictor of progression-free survival in several multivariateg Gene Expression Programs Both in Cancer Cells and in Fibroblasts
C. D2A1mousemammary tumor cells stably expressing dsRed (D2A1-dsRed)
cer cells were either visualized by fluorescent microscopy (A) or trypsinized and
s shown. Error bars, SEM. **p < 0.005.
wn with or without WT or Hsf1 null MEFs and sorted as described above. RNA
nalyzed using cluster 3.0. For each gene, expression in D2A1 cells grown alone
sf1 null MEFs was calculated.
e of WT or Hsf1 null MEFs.
d in D2A1 cells grown in coculture withWT versusHsf1 null MEFs (in duplicate).
c correspond to groups a and c in (C).
(A), but not treated with mitomycin C. After 72–96 hr, cultures were sorted, and
out D2A1 cells and processed in the same manner served as controls. Gene
s were clustered into four groups. GO enrichment is shown to the right of the
s cocultured with cancer cells (groups 1 and 4 in E). Enrichment was calculated
). Statistically significant enrichment (false discovery rate [FDR] q value < 0.05)
Cell 158, 564–578, July 31, 2014 ª2014 Elsevier Inc. 571
(legend on next page)
572 Cell 158, 564–578, July 31, 2014 ª2014 Elsevier Inc.
models consideringKRAS andEGFRmutational status as well as
clinicopathologic factors (Table S7). These clinical association
data suggest that HSF1 status could serve as a promising inde-
pendent prognostic marker in lung cancer as well as breast
cancer.
DISCUSSION
For cancer cells to proliferate, invade, and metastasize, they
must recruit and reprogram nonmalignant stromal cells. We
find that HSF1 activation is a key factor in the transcriptional re-
programming of the stroma from a tumor-repressive environ-
ment to a supportive one. At least two central signaling pathways
in the tumor microenvironment are empowered by HSF1: path-
ways mediated by TGF-b and by SDF1. Establishing the rele-
vance of our experimental findings to human disease, HSF1
was activated in the stroma of a wide variety of human cancers,
and this activation correlated strongly with poor outcome in both
lung and breast cancer.
Our work establishes a role for stromal HSF1 in tumor biology
that is distinct, yet highly complementary, to its recently estab-
lished role in malignant cells. HSF1 has historically been viewed
as a stress-activated transcription factor. In tumors, stromal and
cancer cells alike must cope with a variety of potentially lethal
challenges, including oxidative stress, nutrient deprivation, and
protein misfolding. Yet, neither the cancer HSF1 program we
previously reported in malignant cells (Mendillo et al., 2012) nor
the stromal HSF1 program we report here is a simple reflection
of these inevitable stresses.
The cancer HSF1 program supports the malignant lifestyle of
cancer cells in a multitude of ways, including direct effects on
cell cycle, DNA repair, anabolic metabolism, and proliferation
(Jin et al., 2011; Mendillo et al., 2012; Meng et al., 2010; Santa-
gata et al., 2013). The stromal HSF1 program drives pathways
that are of specific benefit to the malignant elements within the
tumor. These pathways facilitate angiogenesis, ECM organiza-
tion, adhesion, and migration.
Clearly, HSF1 is capable of driving highly divergent transcrip-
tional programs depending on the cellular context. One feature
of these programs, which we have begun to unravel, is the way
HSF1 responses are coordinated between cancer cells andFigure 4. TGF-b and SDF1 Mediate the Support of Cancer Cell Growth
(A) The relative expression of Sdf1, Tgf-b1, and Tgf-b2 in WT orHsf1 null immortali
of three experiments is shown. Error bars, SEM.
(B and C) WT or Hsf1 null immortalized MEFs were cocultured with D2A1-dsRed
and 100 ng/ml SDF1. After 96 hr, cells were either visualized by fluorescent micros
coculture is presented. The experiment was repeated three times, in triplicate.
control.
(D) Immortalized WT or Hsf1 null mitomycin-treated MEFs were pretreated, or not
were continued for 72 hr, with daily supplementation of LY2109761 (or not, as con
triplicate. Results are expressed as the mean relative number of cancer cells, no
(E) Immortalized WT MEFs stably expressing small hairpin RNAs targeting Sma
analyzed as in (C). The percentage of cancer cells in the coculture is presented.
(F) ChIP was performed with anti-HSF1 antibodies usingmaterial prepared fromM
analyzed by qPCR with primers targeting potential heat shock elements in mouse
expected to be amplified, were used as a negative control (Neg. Cont.). The e
experiment. Representative results from one experiment are shown as mean ± S
*p < 0.05; **p < 0.01. See also Figure S4.stroma. We have found that TGF-b and SDF1 are two extracel-
lular mediators of the HSF1 program in CAFs. Although it was
previously recognized that these proteins, when secreted by
CAFs, enhance the protumorigenic phenotype (Kojima et al.,
2010), the factors responsible for their upregulation were un-
known. HSF1 has been shown to directly bind to HSEs in the
genes of several chemokines (Henderson and Kaiser, 2013;
Maity et al., 2011) during heat shock. Conversely, HSF1 can
be activated by exposure to cytokines such as TGF-b and
interleukin-1b in vitro (Sasaki et al., 2002). Taking these obser-
vations together, we suggest that reciprocal interactions be-
tween secreted cytokines and intracellular HSF1 programs
that are normal responses to fever and infection have been
co-opted by diverse cell types in tumors to fuel the malignant
state.
But how did such non-cell-autonomous HSF1 programs
evolve? The HSF1-dependent heat shock response has tradi-
tionally been conceived as an internally driven cellular response
to proteotoxic stress. However, recent work in C. elegans has
established that HSF1 can be activated in a non-cell-autono-
mous manner. Acute stresses detected by thermosensory neu-
rons can orchestrate HSF1-dependent heat shock responses
throughout the animal. This coordinated response benefits the
organism as a whole (Prahlad et al., 2008). Similarly, in tumors,
cancer cells induce the activation of HSF1 in the stroma, and
this activation benefits the tumor as a whole (albeit to the detri-
ment of the patient). But, in addition to this, in stroma, the HSF1-
regulated program itself is non-cell autonomous. It results in
secretion of factors that act to enhance the survival and
proliferation of neighboring cancer cells. We suggest that the
interplay between HSF1 responses in cancer cells and stroma
has its origins in ancient biological mechanisms that act to pro-
mote the survival of multicellular organisms in a non-cell-auton-
omous way.
The complementary but distinct roles of HSF1 in cancer and
stromal cells of tumors have both diagnostic and therapeutic
implications. From a diagnostic perspective, assessing HSF1
in both stromal and cancer cells might help to guide treatment
choices in early-stage cancers, especially lung cancer, where
currently there are no reliable markers for gauging malignant po-
tential other than tumor size. The increased surveillance ofby Stromal HSF1
zedMEFs wasmeasured by qPCR and normalized (norm.) toGapdh. Themean
cells as explained in Figure 3A, in the presence or absence of 10 ng/ml TGF-b1
copy (B) or quantitated by flow cytometry (C). The percentage of cancer cells in
Representative results of one experiment are shown as mean ± SEM. Cont,
, with LY2109761 for 30 min before coculture with D2A1-dsRed cells. Cultures
trol), and then analyzed as in (C). The experiment was repeated three times, in
rmalized to nondrug-treated cocultures with WT MEFs. Error bars, SEM.
d2 (shSmad2) or GFP (shGFP) were cocultured with D2A1 cells, treated and
CF7 tumor xenografts. Normal rat IgG served as a negative IP control. IPs were
Sdf1 and Tgf-b2. Primers targeting an intergenic region in the mouse DNA, not
xperiment was repeated twice; tumors from three mice were used for each
EM.
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Figure 5. Increased HSF1 Activation in the Stroma Is Associated with Decreased Survival in Breast Cancer Patients
(A–C) Analysis of HSF1 mRNA expression levels in the stroma of 53 breast cancer patients from Finak et al. (2008).
(A) The association between HSF1 expression and tumor grade is presented in a box and whiskers plot.
(B) KM analysis of patients stratified by HSF1 expression.
(C) The correlation between HSF1 expression and HER2 status is presented in a box and whiskers plot. HER2-neg, HER2 negative; HER2-pos, HER2 positive.
(D) Breast cancer resections from 46 early-stage patients were stained with anti-HSF1 antibodies and scored for HSF1 protein activation (relative nuclear staining
intensity) in the stroma by IHC. Association of stromal HSF1 activation with disease-free survival was assessed by KM analysis. int, intermediate; h/i, high/
intermediate; h/l, high/low.
*p < 0.05. See also Figure S5 and Table S6.patients at high risk of developing lung cancer is creating an
acute need for markers that can predict which early-stage tu-
mors are most likely to progress, in order to avoid overtreatment
and its associated morbidities. The widespread activation of
stromal HSF1 in diverse cancers suggests that it might be a
useful biomarker in other tumor types as well, as we have shown
for breast cancer. From a therapeutic perspective, the depen-
dence of even the most robust cancers on supporting stromal
cells, and the relative genetic stability of the stroma, make
HSF1 an attractive target for intervention in both cancer cells
and stroma (Bissell and Hines, 2011; Luo et al., 2009; Place
et al., 2011; Saturno et al., 2013; Whitesell and Lindquist,
2009). As we and others have suggested, the nearly unthwart-
able ability of advanced cancers to evolve resistance to virtually
every available therapy makes it attractive to target normal bio-
logical networks that have been co-opted to support malig-574 Cell 158, 564–578, July 31, 2014 ª2014 Elsevier Inc.nancy, rather than relying solely on the targeting of mutated ma-
lignant drivers.
EXPERIMENTAL PROCEDURES
Ethics Statement
All clinical data were collected following approval by the Rabin Medical Center
institutional review board (breast cohort) and the Partners Health Care institu-
tional review board (lung cohort). All animal studies were conducted in accor-
dance with the Guide for the Care and Use of Laboratory Animals of the NIH.
Mice were maintained according to the guidelines of the MIT Committee on
Animal Care (CAC), and study designs were approved by the MIT CAC (proto-
col # 0612-055-15).
Cell Culture
D2A1, 4T7,MCF7, andMEFswere cultured in Dulbecco’smodified Eagle’sme-
dium with 10% fetal bovine serum (FBS). HCC38, A549, and H1703 cells were
cultured in RPMI with 10% FBS. For coculture, immortalized MEFs were plated
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Figure 6. Increased HSF1 Activation in the Stroma Is Associated with Decreased Survival in Lung Cancer Patients
(A) Lung cancer resections from five patients were stained with anti-HSF1 (brown), anti-SMA (brown), or a combination of both antibodies (HSF1 in brown; SMA in
red). Representative images are shown.
(B and C) Lung cancer resections from 72 patients with stage I disease were stained with anti-HSF1 antibodies and scored for HSF1 activation in the stromal cells
and in the cancer cells.
(B) HSF1 stromal scores are correlated with disease-free survival by KM analysis.
(C) KM analysis of disease-free survival for patients with concordant high or low HSF1 scores in both stromal cells and cancer cells.
(D) Stromal HSF1 levels in KRAS mutant tumors (n = 18) from the lung cancer cohort correlate with disease-free survival by KM analysis.
See also Figure S6 and Table S7.at near confluency and 24 hr later, treated, where indicated, with 10 mg/ml mito-
mycin C (Sigma-Aldrich) for 2 hr and washed with PBS. Cancer cells were
seeded on top of the MEFs (1:5 ratio of cancer cells:MEFs) and allowed to
grow for 72–96 hr. Where indicated, MEFs were incubated with LY2109761(1 mM; Selleck Chemicals) for 30 min before seeding of cancer cells. The same
concentration of inhibitor was then added daily. Recombinant TGF-b1 (R&D
Systems; 240-B-002) andSDF1 (R&DSystems; 460-SD-010)were added to co-
cultures at the indicated concentrations once, when coculture was started.Cell 158, 564–578, July 31, 2014 ª2014 Elsevier Inc. 575
Bi-Tet-Hsf1 MEFs
Bi-Tet-Hsf1 MEFs were constructed as explained in Extended Experimental
Procedures. Where indicated, cells were treated with 2 mg/ml doxycycline to
inhibit Hsf1 expression.
Flow Cytometry
For expression profiling, cocultures were sorted using a FACSAria (BD Biosci-
ences) instrument, as explained in Extended Experimental Procedures. For all
other experiments, a Guava EasyCyte (Millipore) cytometer was used, 10,000
cells/sample were analyzed, and the fraction of cancer cells was calculated
using FlowJo 8.8.7 software.
Gene Expression Analysis
Duplicate RNA samples were reverse transcribed and hybridized to duplicate
SurePrint Agilent microarrays (Agilent Technologies; G4852A). Data were
analyzed using Cluster, GOrilla, and MSigDB and visualized using Java Tree-
View (details in Extended Experimental Procedures).
Small Hairpin RNA Knockdown of Genes in the TGF-b and SDF1
Signaling Networks
The following genes were stably knocked down in D2A1 cells and in MEFs:
Smad2, Smad3, Smad4, and Tgf-bR2 (details in Extended Experimental
Procedures).
Xenografts
MCF7 cells (1 3 106) were inoculated subcutaneously in the right inguinal
region of each mouse. Where indicated, 1 3 106 MCF7 cells were mixed
with 3 3 106 WT or Hsf1 null primary MEFs prior to injection. Tumor growth
was monitored by caliper measurements twice weekly. Mice were sacrificed,
and tumors were excised when volume reached 1.5 cm3 or overlying skin
became ulcerated. Half the resected tissue was flash frozen for ChIP and
half fixed in 10% formalin, processed using standard methods, cut into
5 mm sections, and immunostained as described below.
ChIP-qPCR
Flash-frozen tumor xenografts (0.5 cm3 each) were pulverized, fixed in
formalin, and processed as described previously (Lee et al., 2006; Mendillo
et al., 2012). Anti-HSF1 (Thermo Scientific; RT-629-PABX) was used to immu-
noprecipitate (IP) HSF1, and normal rat immunoglobulin G (IgG) (Jackson
ImmunoResearch Laboratories; 012-000-003) was used as control. qPCR
was performed using the primers listed in Extended Experimental Procedures.
IHC of Tissues, Scoring, and Patient Outcome Analysis
Paraffin blocks and tissuemicroarrays were retrieved, processed, stained, and
scored as described in Extended Experimental Procedures. Outcome analysis
was performed on 46 breast cancer patients and 72 lung cancer patients. Time
to progression of disease and overall survival were estimated by the Kaplan-
Meier (KM) method using GraphPad Prism 6 software. Unless indicated other-
wise, the log rank test was used to assess statistical significance. All statistical
tests were two sided; p < 0.05 was considered statistically significant. Multi-
variate Cox proportional hazards regression analysis was performed using
the coxph function in the survival package in R (http://www.r-project.org/).
EGFR and KRAS Genotyping
Total nucleic acid was extracted from formalin-fixed, paraffin-embedded sur-
gical specimens of the lung cohort described above using a modified Forma-
Pure System (Agencourt Bioscience). SNaPshot mutational analysis of a panel
of cancer genes that included EGFR and KRAS was performed using primers
listed in the Extended Experimental Procedures as previously described (Dias-
Santagata et al., 2010).
Stromal HSF1 mRNA Profiling and Patient Outcome Analysis
Stromal gene expression-profiling data and clinical outcome for 53 breast can-
cers were obtained from Gene Expression Omnibus (GEO) (GSE9014) and the
Finak et al. study (Finak et al., 2008). Analysis was performed as explained in
Extended Experimental Procedures. Survival distributions in the patients with
low stromal HSF1 and high stromal HSF1were compared by KM analysis. The576 Cell 158, 564–578, July 31, 2014 ª2014 Elsevier Inc.associations between HSF1 expression, tumor grade and molecular subtype
are presented by box and whisker plots. Statistical significance was assessed
with the log rank test using GraphPad Prism 6. All statistical tests were two
sided; p < 0.05 was considered significant.
ACCESSION NUMBERS
Microarray raw data were deposited in a public database (GEO accession
GSE56252).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
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